Ignite Creation Date:
2024-05-06 @ 7:42 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06109467
Status:
RECRUITING
Last Update Posted:
2024-05-03
First Post:
2023-10-25
Brief Title:
Neratinib In Combination With ChemotherapyTrastuzumabPembrolizumab In HER2 Gastroesophageal Cancer
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Phase II Study Of Neratinib In Combination With ChemotherapyTrastuzumabPembrolizumab In HER2 Overexpressing Gastroesophageal Cancers
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to test the effects both good and bad of the research study drug Neratinib in combination with Trastuzumab Pembrolizumab and FOLFOX chemotherapy This study will also look at the safety of Neratinib in combination with Trastuzumab Pembrolizumab and FOLFOX in HER2 overexpressing Gastroesophageal cancers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None